Cardeas Pharma, **founded in 2010**, is a biotechnology and healthcare company that is making significant strides in the fight against highly resistant Gram-negative bacilli. The company is advancing a unique antibiotic formulation that combines two drugs with synergistic effects, targeting pathogens such as Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae, as well as biofilms and Gram-positive pathogens including MRSA.
One of the key innovations by **Cardeas Pharma** is the delivery system for this antibiotic formulation. Administered through a single-patient use, vibrating-plate nebulizer compatible with all ventilators, the device produces small, uniform aerosol droplets to efficiently deliver the drug to the small airways and alveoli.
The most recent significant milestone for the company was a **$37.50M Series B investment** on **April 10, 2015**, led by a consortium of investors including **Avalon Ventures, H.I.G. BioHealth Partners, Delphi Ventures, Devon Park BioVentures, Novo Ventures**, and the **Washington Research Foundation**.
This recent investment highlights the confidence of the investment community in **Cardeas Pharma's** innovative approach to combatting antibiotic resistance, indicating the potential for significant clinical outcomes compared to current standard therapies. The company's continued progress in this crucial area of healthcare makes it a compelling prospect for venture capital firms looking to support groundbreaking solutions in the biotechnology and healthcare industries.
